Global Use of Casein Glycomacropeptide Protein Substitutes for Phenylketonuria (PKU): Health Professional Perspectives
There is global inconsistency in access to cGMP PS suitable for PKU, and in the interpretation of evidence-based research. Some professionals have significant concerns about its nutritional composition particularly residual Phe, limiting its estimated use to approximately 25% of PKU patients globally.
Authors
- Rani K. Singh (ORCID: https://orcid.org/0000-0001-9343-6070)
- Fatma Ilgaz (ORCID: https://orcid.org/0000-0002-6518-0255)
- Martina Tosi (ORCID: https://orcid.org/0000-0003-4859-5288)
- Juri Zuvadelli (ORCID: https://orcid.org/0009-0009-9750-3360)
- Suzanne Ford (ORCID: https://orcid.org/0000-0003-1041-2116)
- Maria Inês Gama
- Ozlem Yilmaz Nas
- Sharon A. Evans
- Anne Daly
- Anita MacDonald (ORCID: https://orcid.org/0000-0002-2896-3509)
- Alex Pinto
- Kirsten Ahring
- Catherine Ashmore
- Richard Jackson
- Melanie Hill
Institutions
- AOL (United States) (US)
- University of Liverpool (GB)
- Ankara University (TR)
- Emory University (US)
- University of Milan (IT)
- Bristol Royal Hospital for Children (GB)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Birmingham Children's Hospital (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Ospedale San Paolo (IT)
- Hacettepe University (TR)
- Pomeranian Medical University (PL)
Publication Details
- Journal
- Nutrients
- Published
- 2026-02-02
- DOI
- https://doi.org/10.3390/nu18030488
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00